Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caris Life Sciences (CAI) Other Non-Current Assets (2024 - 2025)

Caris Life Sciences (CAI) has 2 years of Other Non-Current Assets data on record, last reported at $45.3 million in Q4 2025.

  • For Q4 2025, Other Non-Current Assets rose 11.03% year-over-year to $45.3 million; the TTM value through Dec 2025 reached $45.3 million, up 11.03%, while the annual FY2025 figure was $45.3 million, 11.03% up from the prior year.
  • Other Non-Current Assets reached $45.3 million in Q4 2025 per CAI's latest filing, down from $47.0 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $47.0 million in Q3 2025 and bottomed at $40.8 million in Q4 2024.